title: Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
abstract: The size of the pool of resting CD4+ T cells containing replication-competent HIV in the blood of patients receiving intermittent interleukin (IL)-2 plus highly active anti-retroviral therapy (HAART) was significantly lower than that of patients receiving HAART alone. Virus could not be isolated from the peripheral blood CD4+ T cells in three patients receiving IL-2 plus HAART, despite the fact that large numbers of resting CD4+ T cells were cultured. Lymph node biopsies were done in two of these three patients and virus could not be isolated. These results indicate that the intermittent administration of IL-2 with continuous HAART may lead to a substantial reduction in the pool of resting CD4+ T cells that contain replication-competent HIV.
authors.affiliation: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. twchun@nih.gov
authors.forename: T W
authors.initials: TW
authors.lastname: Chun
authors.forename: D
authors.initials: D
authors.lastname: Engel
authors.forename: S B
authors.initials: SB
authors.lastname: Mizell
authors.forename: C W
authors.initials: CW
authors.lastname: Hallahan
authors.forename: M
authors.initials: M
authors.lastname: Fischette
authors.forename: S
authors.initials: S
authors.lastname: Park
authors.forename: R T
authors.initials: RT
authors.lastname: Davey
authors.forename: M
authors.initials: M
authors.lastname: Dybul
authors.forename: J A
authors.initials: JA
authors.lastname: Kovacs
authors.forename: J A
authors.initials: JA
authors.lastname: Metcalf
authors.forename: J M
authors.initials: JM
authors.lastname: Mican
authors.forename: M M
authors.initials: MM
authors.lastname: Berrey
authors.forename: L
authors.initials: L
authors.lastname: Corey
authors.forename: H C
authors.initials: HC
authors.lastname: Lane
authors.forename: A S
authors.initials: AS
authors.lastname: Fauci
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000821:virology*; D003430:Cross-Sectional Studies; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000472:pathogenicity; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000821:virology; D018655:Lymphocyte Count / Q000187:drug effects; D012367:RNA, Viral / Q000097:blood; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D007376:Interleukin-2; D012367:RNA, Viral